Shanghai-based Excalipoint secures rights to two preclinical T-cell engagers from Lepu Biopharma, aiming to fast-track development for solid …
Shanghai-based Excalipoint secures rights to two preclinical T-cell engagers from Lepu Biopharma, aiming to fast-track development for solid …
From decentralized designs to ethical reform, the NIH Pragmatic Trials Collaboratory closes 2024 with a blueprint for smarter, …
Semaglutide’s latest trial reveals significant reduction in heart failure hospitalizations, expanding its role in cardiometabolic care.
Regulatory approval marks a pivotal moment for psychedelic medicine, as COMPASS Pathways prepares to test psilocybin in treatment-resistant …
GSK’s long-acting biologic reduces exacerbations and improves lung function in eosinophilic asthma, offering a potential once-yearly treatment option.
NIH-supported study demonstrates that turning off the prion protein gene can dramatically reduce toxic build-up, offering hope for …
NIH-backed research reveals that a simple skin test may revolutionize early diagnosis of Parkinson’s and related neurodegenerative disorders.
The bispecific antibody earns full approval after demonstrating durable responses in heavily pre-treated patients.
A new framework aims to harmonize clinical trial data reporting across borders, boosting transparency and accelerating global drug …
FDA mandates clearer drug ads, Merck expands oncology portfolio, and political shifts raise questions about public health leadership.
Already a subscriber? Log in